Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Quadruplet regimens for newly diagnosed myeloma & MRD-tracking of DKRd-treated patients

Ola Landgren • 2 Dec 2018
ASH 2018
Multiple Myeloma Bortezomib Carfilzomib Dexamethasone Lenalidomide
CoMMpass

Ola Landgren, MD, PhD, of the Memorial Sloan Kettering Cancer Center, NY, discusses new quadruplet regimens for newly diagnosed multiple myeloma (MM), specifically daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd). Dr Landgren also covers the bone marrow-based and longitudinal blood-based MRD tracking of this group. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Ola Landgren

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
3:51
Should HR-SMM be treated before progression to NDMM?
Ola Landgren • 20 Dec 2023
3:31
ADVANCE: Dara-KRd versus KRd in patients with NDMM
Ola Landgren • 20 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals